Literature DB >> 18636547

Regulation of Wnt/beta-catenin pathway by cPLA2alpha and PPARdelta.

Chang Han1, Kyu Lim, Lihong Xu, Guiying Li, Tong Wu.   

Abstract

Cytosolic phospholipase A(2)alpha (cPLA(2)alpha) is a rate-limiting key enzyme that releases arachidonic acid (AA) from membrane phospholipid for the production of biologically active lipid mediators including prostaglandins, leukotrienes and platelet-activating factor. cPLA(2)alpha is translocated to nuclear envelope in response to intracellular calcium increase and the enzyme is also present inside the cell nucleus; however, the biological function of cPLA(2)alpha in the nucleus remains unknown. Here we show a novel role of cPLA(2)alpha for activation of peroxisome proliferator-activated receptor-delta (PPARdelta) and beta-catenin in the nuclei. Overexpression of cPLA(2)alpha in human cholangiocarcinoma cells induced the binding of PPARdelta to beta-catenin and increased their association with the TCF/LEF response element. These effects are inhibited by the cPLA(2)alpha siRNA and inhibitors as well as by siRNA knockdown of PPARdelta. Overexpression of PPARdelta or treatment with the selective PPARdelta ligand, GW501516, also increased beta-catenin binding to TCF/LEF response element and increased its reporter activity. Addition of AA and GW501516 to nuclear extracts induced a comparable degree of beta-catenin binding to TCF/LEF response element. Furthermore, cPLA(2)alpha protein is present in the PPARdelta and beta-catenin binding complex. Thus the close proximity between cPLA(2)alpha and PPARdelta provides a unique advantage for their efficient functional coupling in the nucleus, where AA produced by cPLA(2)alpha becomes immediately available for PPARdelta binding and subsequent beta-catenin activation. These results depict a novel interaction linking cPLA(2)alpha, PPARdelta and Wnt/beta-catenin signaling pathways and provide insight for further understanding the roles of these key molecules in human cells and diseases. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636547      PMCID: PMC2593467          DOI: 10.1002/jcb.21852

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  64 in total

1.  The PPARalpha-leukotriene B4 pathway to inflammation control.

Authors:  P R Devchand; H Keller; J M Peters; M Vazquez; F J Gonzalez; W Wahli
Journal:  Nature       Date:  1996-11-07       Impact factor: 49.962

Review 2.  Properties and regulation of cytosolic phospholipase A2.

Authors:  C C Leslie
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

3.  "Cytosolic" phospholipase A2 is in the nucleus of subconfluent endothelial cells but confined to the cytoplasm of confluent endothelial cells and redistributes to the nuclear envelope and cell junctions upon histamine stimulation.

Authors:  M R Sierra-Honigmann; J R Bradley; J S Pober
Journal:  Lab Invest       Date:  1996-03       Impact factor: 5.662

4.  Role of cytosolic phospholipase A2 in allergic response and parturition.

Authors:  N Uozumi; K Kume; T Nagase; N Nakatani; S Ishii; F Tashiro; Y Komagata; K Maki; K Ikuta; Y Ouchi; J Miyazaki; T Shimizu
Journal:  Nature       Date:  1997-12-11       Impact factor: 49.962

5.  Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2.

Authors:  T Nagase; N Uozumi; S Ishii; K Kume; T Izumi; Y Ouchi; T Shimizu
Journal:  Nat Immunol       Date:  2000-07       Impact factor: 25.606

6.  Translocation of cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis.

Authors:  M Peters-Golden; K Song; T Marshall; T Brock
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

7.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

Authors:  S A Kliewer; J M Lenhard; T M Willson; I Patel; D C Morris; J M Lehmann
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

8.  Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum.

Authors:  A R Schievella; M K Regier; W L Smith; L L Lin
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

9.  A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice.

Authors:  Takahide Nagase; Naonori Uozumi; Tomoko Aoki-Nagase; Kan Terawaki; Satoshi Ishii; Tetsuji Tomita; Hiroshi Yamamoto; Kohei Hashizume; Yasuyoshi Ouchi; Takao Shimizu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-12-27       Impact factor: 5.464

10.  Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2.

Authors:  Z Huang; P Payette; K Abdullah; W A Cromlish; B P Kennedy
Journal:  Biochemistry       Date:  1996-03-26       Impact factor: 3.162

View more
  10 in total

1.  Retraction: Rgulation of Wnt/ß-catenin pathway by cPLA2 and PPARδ.

Authors: 
Journal:  J Cell Biochem       Date:  2015-04       Impact factor: 4.429

Review 2.  Bioanalysis of eukaryotic organelles.

Authors:  Chad P Satori; Michelle M Henderson; Elyse A Krautkramer; Vratislav Kostal; Mark D Distefano; Mark M Distefano; Edgar A Arriaga
Journal:  Chem Rev       Date:  2013-04-10       Impact factor: 60.622

3.  Phospholipase A2-activating protein is associated with a novel form of leukoencephalopathy.

Authors:  Tzipora C Falik Zaccai; David Savitzki; Yifat Zivony-Elboum; Thierry Vilboux; Eric C Fitts; Yishay Shoval; Limor Kalfon; Nadra Samra; Zohar Keren; Bella Gross; Natalia Chasnyk; Rachel Straussberg; James C Mullikin; Jamie K Teer; Dan Geiger; Daniel Kornitzer; Ora Bitterman-Deutsch; Abraham O Samson; Maki Wakamiya; Johnny W Peterson; Michelle L Kirtley; Iryna V Pinchuk; Wallace B Baze; William A Gahl; Robert Kleta; Yair Anikster; Ashok K Chopra
Journal:  Brain       Date:  2016-12-21       Impact factor: 13.501

Review 4.  Wnt signalling and the control of cellular metabolism.

Authors:  Jaswinder K Sethi; Antonio Vidal-Puig
Journal:  Biochem J       Date:  2010-03-15       Impact factor: 3.857

5.  β-Catenin and peroxisome proliferator-activated receptor-δ coordinate dynamic chromatin loops for the transcription of vascular endothelial growth factor A gene in colon cancer cells.

Authors:  Injoo Hwang; Jeeho Kim; Sunjoo Jeong
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

6.  A missense mutation in PPARD causes a major QTL effect on ear size in pigs.

Authors:  Jun Ren; Yanyu Duan; Ruimin Qiao; Fei Yao; Zhiyan Zhang; Bin Yang; Yuanmei Guo; Shijun Xiao; Rongxin Wei; Zixuan Ouyang; Nengshui Ding; Huashui Ai; Lusheng Huang
Journal:  PLoS Genet       Date:  2011-05-05       Impact factor: 5.917

7.  A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma.

Authors:  Elisa Paolicchi; Paola Pacetti; Elisa Giovannetti; Andrea Mambrini; Massimo Orlandi; Francesco Crea; Antonello A Romani; Roberta Tartarini; Romano Danesi; Godefridus J Peters; Maurizio Cantore
Journal:  Oncol Lett       Date:  2013-09-02       Impact factor: 2.967

8.  PPARD is an Inhibitor of Cartilage Growth in External Ears.

Authors:  Zhen Zhang; Yanyu Duan; Zhongping Wu; Hui Zhang; Jun Ren; Lusheng Huang
Journal:  Int J Biol Sci       Date:  2017-05-16       Impact factor: 6.580

9.  Identification of biomarkers of human skin ageing in both genders. Wnt signalling - a label of skin ageing?

Authors:  Evgenia Makrantonaki; Thore C Brink; Vasiliki Zampeli; Rana Mohsen Elewa; Barbara Mlody; Amir M Hossini; Bjoern Hermes; Ulf Krause; Juergen Knolle; Marwa Abdallah; James Adjaye; Christos C Zouboulis
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice.

Authors:  Gayathri Balandaram; Lance R Kramer; Boo-Hyon Kang; Iain A Murray; Gary H Perdew; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicology       Date:  2016-07-15       Impact factor: 4.571

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.